Bayer gets European approval for Xarelto

5 October 2008

Germany's Bayer Healthcare has been granted European marketing approval for its once-daily anticoagulant Xarelto (rivaroxaban) for the prevention of venous blood clots in adult patients undergoing elective hip or knee replacement surgery. The approval is based on a review of the data for the extensive RECORD clinical program involving almost 10,000 patients across three Phase III trials comparing the drug to market leader Sanofi-Aventis' Lovenox (enoxaparin). Bayer says it will begin the product's launch in European Union member states "very soon."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight